Viking Therapeutics Concludes Enrolment in Phase III Trial of Obesity Therapy

Viking Therapeutics concludes enrolment in Phase III trial of obesity therapy

Viking Therapeutics has concluded participant enrolment in its Phase III VANQUISH-1 trial of subcutaneous VK2735, which is being developed to potentially treat metabolic disorders such as obesity.The post Viking Therapeutics concludes enrolment in Phase III trial of obesity therapy appeared first on Clinical Trials Arena.

Viking completes enrolment in VANQUISH-1 Trial of VK2735

Viking Therapeutics has completed patient enrolment in its Phase 3 VANQUISH-1 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.The Phase 3 VANQUISH-1 study is a randomised, double-blind, plac…